Quick Answer
MAXCYTE, INC. reported Research And Development Expense of $20.82 million for the year ending 2025.
- MAXCYTE, INC. showed a decrease of -6.3% in Research And Development Expense from 2024 to 2025.
- This data is from MAXCYTE, INC.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $4.09 million | Q3 2020: $4.52 million | Q1 2021: $6.08 million | Q2 2021: $3.20 million | Q3 2021: $2.75 million | Q1 2022: $3.77 million | Q2 2022: $4.70 million | Q3 2022: $5.33 million | Q1 2023: $6.05 million | Q2 2023: $5.66 million | Q3 2023: $6.26 million | Q1 2024: $6.68 million | Q2 2024: $5.62 million | Q3 2024: $5.32 million | Q1 2025: $5.90 million | Q2 2025: $6.27 million | Q3 2025: $5.32 million.
- Over the full 7 years of available data (2019 to 2025), MAXCYTE, INC.'s Research And Development Expense has grown by 18.4%.
- Historical annual values: Fiscal year 2025: $20.82 million | Fiscal year 2024: $22.23 million | Fiscal year 2023: $23.82 million | Fiscal year 2022: $19.51 million | Fiscal year 2021: $15.41 million | Fiscal year 2020: $17.73 million | Fiscal year 2019: $17.59 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: